Cord blood infusion trial aims to beat long COVID fatigue
NCT ID NCT07184385
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 3 trial tests whether a single infusion of human umbilical cord blood, called REGENECYTE, can reduce fatigue in people with Long COVID. Sixty adults with post-COVID condition will receive either the cord blood or a placebo (salt water) and be monitored for changes in fatigue and side effects. The study is double-blind and randomized, meaning neither participants nor doctors know who gets the real treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
human umbilical cord blood (REGENECYTE)
What this could lead to
If it works, this could offer a new treatment to ease severe fatigue in people with Long COVID.
What could go wrong
This is a small early-stage trial with only 60 people, so results may not apply to everyone. The treatment is an infusion, which carries risks like allergic reactions or infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••